文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

呼吸道合胞病毒与美国儿科重症监护资源利用

Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization.
PubMed 文献 · JAMA Netw Open · 2024-10-01
一句话结论RSV占儿科ICU入住11.4%、ICU天数21.1%;若65%~85%符合条件儿童接受RSV预防,估计可减少2.1%~2.8%的儿科ICU入住和4.5%~5.9%的ICU天数。

这项回顾性横断面研究基于Oracle Cerner RealWorld Data全国电子病历数据库,分析2017年1月1日至2023年6月1日美国53家医院119 782例儿科ICU入住记录。11.4%的ICU入住与RSV相关,其中38.6%符合预防条件;RSV相关入住占ICU天数的21.1%,其中43.8%符合预防条件。RSV相关入住较无RSV入住更多使用正压通气(29.7% vs 17.7%,P < .001)和血管活性药物(22.3% vs 17.5%,P < .001)。作者估计若65%~85%符合条件儿童接受RSV预防,可减少2.1%~2.8%的儿科ICU入住和4.5%~5.9%的ICU天数。

要点

  • 119 782例儿科ICU入住中13 702例(11.4%)与RSV相关,其中5217例(38.6%)符合预防条件,占总ICU入住的4.4%。
  • RSV相关入住占ICU总天数的21.1%(109 334天),其中47 888天(43.8%)符合预防条件,占总ICU天数的9.2%。
  • RSV相关入住较无RSV入住更多使用正压通气(4074例[29.7%] vs 18 821例[17.7%],P < .001)。
  • RSV相关入住较无RSV入住更多使用血管活性药物(3057例[22.3%] vs 18 570例[17.5%],P < .001)。
  • 作者估计若65%~85%符合条件儿童接受RSV预防,可减少2.1%~2.8%的儿科ICU入住和4.5%~5.9%的儿科ICU天数。

适用人群与场景

  • 2017年1月1日至2023年6月1日期间入住ICU的所有儿童(年龄>1天且<18岁),数据来自美国Oracle Cerner RealWorld Data全国电子病历数据库53家医院。

研究设计与关键结果

  • 回顾性横断面研究,纳入53家医院119 782例儿科ICU入住;65 757例(54.9%)为男性;中位(IQR)年龄4.5(1.1-12.5)岁,中位(IQR)ICU住院时长1.8(1.0-3.9)天。
  • 13 702例(11.4%)ICU入住与RSV相关,其中5217例(38.6%)符合预防条件(占总ICU入住的4.4%)。
  • RSV相关入住占ICU天数的21.1%(109 334天),其中47 888天(43.8%)符合预防条件(占总ICU天数的9.2%)。
  • RSV相关入住较无RSV入住更多使用正压通气(4074例[29.7%] vs 18 821例[17.7%];P < .001)。
  • RSV相关入住较无RSV入住更多使用血管活性药物(3057例[22.3%] vs 18 570例[17.5%];P < .001)。
  • 作者估计若65%~85%符合条件儿童接受RSV预防,可减少2.1%~2.8%的儿科ICU入住和4.5%~5.9%的儿科ICU天数。

证据类型、等级与局限

  • 证据类型:回顾性横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,若65%~85%符合条件儿童接受RSV预防,估计可减少2.1%~2.8%的儿科ICU入住和4.5%~5.9%的儿科ICU天数。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Bronchiolitis is the most common diagnosis necessitating respiratory support and pediatric intensive care, and respiratory syncytial virus (RSV) is the most common cause of bronchiolitis. In 2023, the monoclonal antibody nirsevimab and the maternal RSVpreF vaccine were implemented to prevent RSV in infants.

OBJECTIVE: To determine the potential association of novel RSV prevention strategies with pediatric intensive care unit (ICU) utilization.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study examined US pediatric ICU encounters with and without RSV from January 1, 2017, to June 1, 2023. Data were from Oracle Cerner RealWorld Data, a national electronic health record database. All children (aged >1 day and <18 years) admitted to an ICU during the study period were included in the analysis. Statistical analysis was performed from February to May 2024.

MAIN OUTCOMES AND MEASURES: The primary outcomes were ICU encounters with RSV and ICU encounters with RSV eligible for RSV prevention.

RESULTS: There were 119 782 ICU encounters from 53 hospitals; 65 757 encounters (54.9%) were male; median (IQR) age was 4.5 (1.1-12.5) years, median (IQR) ICU length of stay was 1.8 (1.0-3.9) days; 13 702 ICU encounters (11.4%) had RSV, of which 38.6% (5217) were eligible for prevention (4.4% of total ICU encounters). Encounters with RSV accounted for 21.1% (109 334) of ICU days, of which 43.8% (47 888) were eligible for prevention (9.2% of total ICU days). Encounters with RSV were associated with a greater use of positive pressure ventilation (4074 [29.7%] vs 18 821 [17.7%]; P < .001) and vasoactive medications (3057 [22.3%] vs 18 570 [17.5%]; P < .001) compared with those without RSV.

CONCLUSIONS AND RELEVANCE: The findings of this retrospective cross-sectional study of RSV and US pediatric intensive care utilization suggest that if 65% to 85% of eligible children received RSV prevention, an estimated 2.1% to 2.8% reduction in pediatric ICU encounters and an estimated 4.5% to 5.9% reduction in pediatric ICU days could be achieved.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Shanklin A, Olson T, Patel AK, et al. Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization. JAMA Netw Open. 2024. PMID: 39453655. doi:10.1001/jamanetworkopen.2024.40997

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。